Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges

Nadeem, Sarah; Aamdani, Salima Saleem; Ayub, Bushra; Rizvi, Nashia Ali; Arslan, Fatima Safi; Martins, Russell Seth; Khan, Maria; Mahmood, Syed Faisal

doi:https://doi.org/10.1155/2022/4240378

Global Health, Epidemiology and Genomics

On this page

Abstract Introduction Methods Results Discussion Conclusion Data Availability Conflicts of Interest Supplementary Materials References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 4240378 | https://doi.org/10.1155/2022/4240378

Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges

Sarah Nadeem,^1,2Salima Saleem Aamdani,¹Bushra Ayub,¹Nashia Ali Rizvi,¹Fatima Safi Arslan,³Russell Seth Martins,³Maria Khan,³and Syed Faisal Mahmood²

Academic Editor: Osman Faruk Bayramlar

Received03 Jan 2022

Accepted01 Mar 2022

Published20 Apr 2022

Abstract

Background. The coronavirus disease 2019 (COVID-19) pandemic has presented as a therapeutic challenge for clinicians worldwide due to its rapid spread along with evolving evidence and understanding of the disease. Internationally, recommendations to guide the management of COVID-19 have been created and updated continuously by the WHO and CDC, which have been locally adapted by different countries. Similarly, Pakistan’s National Command Operation Center (NCOC), in its national COVID-19 management strategy, generated guidelines for national implementation. Keeping the guidelines updated has proved challenging globally and locally. Here, we present a summary of the process to assess the evidence, including a time-restricted systematic review based on NCOC Clinical Management Guidelines for COVID-19 Infections v4 published on 11^th December 2020 version, correlating it with current recommendations and with input one of the guidelines authors, particularly noting the methodological challenges. Methods. We conducted a systematic review synthesizing global research on treatment options for COVID-19 hospitalized patients, limiting it to pharmacological interventions for hospitalized COVID-19 patients included in Pakistan’s NCOC’s national guidelines v4 published on 11^th December 2020. Each treatment recommendation’s strength and quality of evidence was assessed based on the grading of recommendations assessment, development, and evaluation (GRADE) methodology. These were then compared to the most current living WHO COVID-19 pharmacological treatment guidelines v7.1. One of the authors of the NCOC guidelines reviewed and commented on the findings as well. Results. We note that the data from our systematic review strongly supports corticosteroids use in treating severe and critically ill COVID-19 hospitalized patients correlating with WHO v7.1 guidelines 24 September 2021. However, evidence from our review and WHO v7.1 for the use of tocilizumab had some conflicting evidence, with data from our review until December 2020 supporting only a weak recommendation for its use, compared to the strong recommendation by the WHO for the use of tocilizumab in patients with severe or critical COVID-19 infection. Regarding the use of antibiotics and ivermectin use in treating COVID-19 hospitalized patients, data from our review and WHO v 7.1 recommend against their use. Conclusion. Research data about the efficacy and safety of pharmacological interventions to treat hospitalized patients with COVID-19 are rapidly evolving, and based on it, the evidence for or against recommendations changes accordingly. Our study illustrates the challenges of keeping up with the evidence; the recommendations were based on studies up till December 2021, and we have compared our recommendations with the WHO v7.1, which showed some significant changes in the use of pharmacological treatment options.

1. Introduction

Pakistan, like other countries worldwide, has seen many cases of coronavirus disease 2019 (COVID-19) since the pandemic began [1]. The national government-led response included the creation of a central National Command Operation Center (NCOC), setting up designated hospitals, isolation testing facilities, and following dedicated treatment guidelines based on WHO recommendations. National guidelines were created, 2nd April 2020 (v1), with most recent version (v4) currently in use, “Clinical Management Guidelines for COVID-19 Infections” published by the Government of Pakistan on 11^th December 2020 [2]. These have been formulated by national experts incorporating international guidelines and adapting them to local contexts.

2. Methods

Here, we present a summary of the process to assess the evidence, including a time-restricted systematic review based on NCOC version, correlating it with current recommendations specifically looking at it from a local perspective; along with input from NCOC guidelines.

We describe the methodological challenges that exist in the developing evidence-based guidelines for an evolving pandemic. We performed a systematic review to evaluate the interventions noted in the NCOC guidelines v4 and to GRADE recommendations for pharmacological interventions for hospitalized patients. Then, we compared our recommendations to WHO v7.1 COVID-19 therapeutics guidelines and subsequently invited an expert narrative review by NCOC experts specifically looking at it from a local perspective.

This study was conducted at the Center for Clinical Best Practices (CCBP), Clinical and Translational Research Incubator (CITRIC), Aga Khan University, Karachi, Pakistan, after approval from the institutional ethical review committee.

The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [3]. We aimed to review the effectiveness of pharmacological interventions included in the NCOC guidelines on mortality and length of stay in hospitalized patients with COVID-19 including evidence available until 11^th December 2020. The WHO clinical progression scale for clinical improvement (ordinal scale) was used to categorize the disease severity for each study. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria were used to evaluate and formulate recommendations for or against and strength by considering the quality of evidence and balance between benefits and harms [4] (Table 1 and Supplementary Figure 1).

Studies in English published from 1^st November 2019 to 31^st December 2020 were included in the review. Data extraction and synthesis data extraction were performed by two independent investigators using a structured data extraction form to ensure consistency. Any disagreements were noted and resolved by further discussion with a third investigator. The extracted data are given in Tables 2–5). The quality of the final included studies was assessed according to each study design. Observational studies were assessed by the National Institute of Health Study Quality Assessment Tool [5]. Randomized control trials were evaluated by Cochrane Risk of Bias (RoB) [6]. Quasiexperimental studies were assessed by the Cochrane Effective Practice and Organization of Care (EPOC) risk of bias tool [7] (Supplementary Figures 2–9).

3. Results

In our systematic review, a total of 122 studies were included (Supplementary Figure 1). Data extracted from these final studies are given in Table 2 (cohort and cross-sectional studies), Table 3 (case-control studies), Table 4 (interventional studies), and Table 5 (quasiexperimental studies).

All drugs in the NCOC v4 guidelines were included, and their efficacy was assessed by evaluating length of hospitalization, mortality, and ordinal scores, and a recommendation was made based on GRADE methodology. As per the NCOC panel recommendation, we additionally included colchicine in the review and comparison of WHO, NCOC v4, and our review between drugs, as given in Table 6.

3.1. Corticosteroids

Multiple studies have evaluated the efficacy of corticosteroids in the management of COVID-19 (Tables 2 and 5). We gave strong recommendation for the use of corticosteroids because the studies were showing early recovery in severe and critical patients; however, we gave weak recommendation for its use in noncritical patients as it did not show any positive outcomes. Most of the studies in our systematic review were observational; hence, we gave a moderate quality of evidence.

As per our systematic review, we recommend(i)For the use of corticosteroids in severe and critical patients, hospitalized COVID-19 patients. Strong recommendation, moderate-quality evidence.(ii)Against the use of corticosteroids in nonsevere patients, hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence.

WHO v7.1 dated 24/9/2021 recommended for the use of systematic corticosteroid rather than no corticosteroids in severe and critical COVID-19 patients.

3.2. Tocilizumab

In our systematic review, mortality rates with tocilizumab therapy ranged from 6.98% to 60% (depending on patient inclusion criteria), with many studies showing a protective effect of tocilizumab with regards to mortality, especially if given intravenously (as compared to subcutaneously) and within 12 days of admission [8–28]. Patients treated with tocilizumab alone were more likely to show improvement on the WHO ordinal scale (63.9% vs. 36.1%) and less likely to require ICU care (40.4% vs. 59.6%) as compared to those treated with corticosteroids in addition to tocilizumab [29]. We gave weak recommendation as the studies were showing controversial results on managing COVID-19 hospitalized adults with tocilizumab. Many of the studies were showing inconsistent results; therefore, we gave moderate certainty.

As per our systematic review, we recommend(i)For the use of tocilizumab in hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence.

WHO v7.1 recommended for the use of tocilizumab in patients with severe or critical COVID-19 infection.

3.3. Ivermectin Therapy

Due to its effectiveness in various other viral infections, ivermectin was assessed as a therapeutic agent for COVID-19 infection (Tables 2 and 4). As studies showed no major difference in mortality, we gave weak recommendation for the use of ivermectin and low quality of evidence because of insufficient evidence.

As per our systematic review, we recommend(i)Against the use of ivermectin therapy in the use of COVID-19 hospitalized patients. Weak recommendation, low-quality evidence.

WHO v7.1 recommended against the use of ivermectin in patients with COVID-19.

3.4. Antibiotics

The macrolide azithromycin has demonstrated antiviral activity, especially in human bronchial epithelial cells where it reduces viral cell replication and causes an increase in viral-induced pattern recognition receptors. It has exhibited a synergistic effect with the drug hydroxychloroquine, and together, they decrease the production of inflammatory cytokines such as IL-1 and IL-6 [30]. We gave weak recommendation for the management of COVID-19 hospitalized adults with hydroxychloroquine alone or in combination with other antibiotics because the studies were not showing positive outcomes on mortality and length of stay. We gave moderate certainty of evidence as most of the studies in our systematic review were cohort and case-control studies.

As per our systematic review, we recommend(i)Against the use of antibiotics, including hydroxychloroquine alone or in combination with other antibiotics in hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence.

WHO v7.1 recommended against the use of hydroxychloroquine or chloroquine for treatment of COVID-19.

3.5. Anticoagulation Therapy

As per our systematic review, the therapeutic doses of anticoagulation, i.e., nadroparin calcium (2850 IU) reduced mortality as compared to the prophylactic doses in the majority of studies [31–34]. While few studies found no difference, Billet et al. reported mortality reduction for prophylactic doses of both apixaban and enoxaparin and therapeutic doses of apixaban but not enoxaparin [35–38]. Therapeutic doses of apixaban did not provide an additional mortality reduction compared to prophylactic doses. Therapeutic doses of anticoagulation were shown to reduce the incidence of a venous thromboembolic event; however, both therapeutic and prophylactic doses of anticoagulation reduce in-hospital mortality compared to patients not receiving anticoagulation [31, 33, 35, 39]. We gave strong recommendation to both therapeutic and prophylactic doses of anticoagulants, as in several studies, it has shown to reduce mortality. Many studies in our systematic review were observational, so we rated the evidence as moderate.

As per our systematic review, we recommend(i)For the use of anticoagulant therapeutic doses. Therapeutic: strong recommendation, moderate-quality evidence.(ii)For the use of prophylactic dose anticoagulants to treat COVID-19 hospitalized patients. Prophylactic: strong recommendation, moderate-quality evidence.

No evidence available as per WHO v7.1.

3.6. Antivirals

Remdesivir, an antiviral agent, has been associated with lower mortality, with one study reporting 62% lower odds of mortality and greater clinical improvement [40, 41]. However, the results of other studies have not been as conclusive. Studies using the WHO ordinal scale have found weak associations between remdesivir use and improved patient outcomes [42]. With regards to other antivirals, there are conflicting data from studies. Varying WHO ordinal scale results were found for antivirals lopinavir-ritonavir. Multiple studies found no difference in mortality with the combination of ritonavir/lopinavir and remdesivir [43, 44]. We gave weak recommendation for the use of remdesivir because of the inconsistent results of the studies. However, we recommend against the use of ritonavir/lopinavir use due to conflicting research evidence. Most of the studies on remdesivir were randomized controlled trials; therefore, we rated it as high quality of evidence, while studies on ritonavir/lopinavir were mostly observational, so it has moderate certainty.

As per our systematic review, we recommend(i)For the use of remdesivir in hospitalized COVID-19 patients. Weak recommendation, high-quality evidence.(ii)Against the use of ritonavir/lopinavir in hospitalized COVID-19 patients. No recommendation, moderate-quality evidence.

WHO v7.1: conditional recommendation against administering remdesivir in addition to usual care.

WHO v7.1 recommended against administering lopinavir/ritonavir for treatment of COVID-19.

3.7. Convalescent Plasma

Convalescent plasma initially was looked at as a possible therapy for COVID-19 infection due to its prior usefulness in other epidemic viruses. Some initial observational studies suggested the use of convalescent plasma in improving pulmonary function, decreasing adverse effects, increasing survival, and shortening hospital stay [45–47]. While most observational studies reported positive outcomes, RCTs have not supported convalescent plasma use. We gave weak recommendation for convalescent plasma use because RCTs have not shown significant improvement in patients’ health status. As many of the studies were observational, therefore, we gave it a moderate quality of evidence.

As per our systematic review, we recommend(i)Against the use of convalescent plasma in the management of hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence.

There are no available evidence as per WHO v7.1.

3.8. Famotidine

While famotidine is conventionally used as an H2 receptor blocker, it also has antiviral properties [48]. Freedberg et al., in a single-centered retrospective cohort study, reported reduced mortality with famotidine use [49]. Similarly, when comparing a treatment regimen of HCQ, azathioprine, remdesivir, and corticosteroids with famotidine and those without famotidine, Mather et al. reported lower mortality in the famotidine arm (14% in the famotidine group vs. 26% in the nonfamotidine group) [50]. Despite these results, larger studies and RCTs have not yet established the role of famotidine, and therefore, we gave it low certainty. Given the minimal side effect profile of famotidine, our judgement based on data available at the time was for its use but with weak recommendation.

As per our systematic review, we recommend(i)For the use of famotidine in hospitalized COVID-19 patients. Weak recommendation, low-quality evidence.

There are no available evidence as per WHO v7.1.

3.9. Immunoglobulin Therapy

Based on the limited number of studies, a retrospective cohort study conducted by Shao et al. found IVIG therapy to reduce the 28-day mortality in critically ill patients (27% in the IVIG group vs. 53% in the non-IVIG group) [51]. Similarly, a randomized trial by Gharebaghi et al. also proved that IVIGs reduced mortality [52]. Studies have shown lower mortality; therefore, we supported its use with weak recommendation. As no significant interventional studies are supporting its use, we gave it moderate certainty.

As per our systematic review, we recommend(i)For the use of immunoglobulin therapy in hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence.

There are no available evidence as per WHO v7.1.

3.10. Colchicine

Colchicine works by inhibiting the assembly of microtubules during mitosis by binding to tubulin inside cells and forming tight tubulin-colchicine complexes. This is its major anti-inflammatory mechanism of action [53]. In our review, only 1 single-center cohort of adult hospitalized patients with COVID-19 pneumonia and acute respiratory distress syndrome was found using colchicine 1 mg/day, investigating the association between colchicine use and improved survival in adult hospitalized patients with COVID-19 pneumonia and acute respiratory distress syndrome and found a 20.8% decrease in mortality amongst patients treated with colchicine along with other standards of care drugs [54]. Because of the insufficient research evidence, we are not recommending colchicine use and gave it a low quality of evidence.

As per our systematic review, we recommend(i)Against the use of colchicine in hospitalized COVID-19 patients. No recommendation, low-quality evidence.

There are no available evidence as per the WHO v7.1.

4. Discussion

A great breadth of literature exists on the therapeutic management of hospitalized adults with COVID-19 based on disease severity, much of which have been analyzed and appraised systematically [55]. Currently, living systematic reviews provide information to guide clinical practice [56, 57]. However, this approach assumes that all treatment options are available or approved in each country or region, which is not the case. In Pakistan, the Government of Pakistan has released Clinical Management Guidelines for COVID-19 Infections, based on which clinicians are expected to prescribe and treat patients [2]. While such guidelines are beneficial in which they are region-specific and keep in mind various economic factors and drug availability, they are not regularly updated due to the resources required for systematic reviews and evidence synthesis. To consolidate the pool of information to assess the effectiveness of currently approved therapeutic options for COVID-19 infection in Pakistan, we have synthesized data relating to only those treatments that are recommended in our country’s guidelines using global data from 1^st November 2019 to December 31^st, 2020 [2].

Of all the drug classes analyzed, corticosteroids were found to have the most consistent effect on mortality and length of stay. The WHO clinical progression (ordinal) scale showed a reduction in mortality among patients being treated with corticosteroids. All but a few studies support the use of corticosteroids in patients hospitalized with COVID-19 [58, 59]. Trials that assessed anticoagulation (especially therapeutic vs. prophylactic dosages) were also predominantly found to improve thromboembolic outcomes and mortality. However, variations in the type of anticoagulant used make it hard to recommend a single drug. Nadroparin, tinzaparin, dalteparin (LMWH), heparin, apixaban, and enoxaparin were all found to have reduced mortality [31, 33, 38]. Trials assessing tocilizumab supported its use to limit mortality and length of stay [13, 28, 29, 60]. One study found that the addition of corticosteroids to tocilizumab was a significant protective factor against mortality [61].

Studies assessing remdesivir failed to show any conclusive difference in mortality and length of stays of patients with COVID-19 [42]. Of the antivirals that are being used for COVID-19, lopinavir and ritonavir have predominantly been assessed by various observational studies as well as clinical trials, both of which have been uncertain. Ribavirin alone and in combination with other antivirals (lopinavir/ritonavir + interferon-alpha) was also shown to have minimal efficacy [62]. Data from RCTs led to recommendation against the use of convalescent plasma [63–66], which in the early days of COVID-19 was looked at as a major intervention.

Very few studies have been conducted on famotidine (an H2 receptor blocker) and IVIG. Studies have reported a significantly reduced mortality in patients being treated by famotidine or IVIG compared to control groups; however, further randomized trials and data are needed to make a concrete recommendation. Studies assessing ivermectin also report divided results and highlight the need for further studies. One of the studies assessing colchicine has reported better outcomes in adult hospitalized patients with COVID-19 pneumonia [30].

Our review is the first one to systematically review the drugs specified by the Government of Pakistan’s Clinical Management Guidelines for COVID-19 Infections v4, and several other systematic reviews have been conducted to assess the efficacy of drugs used in the treatment of COVID-19, with the WHO living guidelines for pharmacological management including the most up to date data. It was thus imperative that our findings be compared and assessed against broader literature that has been published.

Our review found the lack of randomized trials to be a limitation for evidence regarding less extensively studied agents, while the more extensively investigated agents had been studied by randomized trials. Since then, newer studies, that have been conducted and included in our review, have shown tocilizumab, IVIGs, and colchicine to be effective as well. Larger trials, such as the solidarity trials, have since proven that remdesivir is not effective [67].

The urgency of information about COVID-19 infection treatment has resulted in poorly organized studies that use a variety of different outcome measures, which deters meaningful comparison between different therapeutic agents. Indeed, our review reported a wide range of outcome measures, resulting in difficulty synthesizing data.

To standardize outcome measures across studies, several international bodies worked in union and formulated a set of outcome measures, which included the WHO clinical progression scale. This is an ordinal scale, ranging from 0 (no infection) to 10 (mortality) that is especially useful in widespread diseases. The lower scores (for mild disease, which may or may not require assistance) are more subjective, and the higher scores (of severe disease requiring different levels of intervention) are likely to change based on regional practices. However, the scale is quick to use because the data required are readily available in medical records. Despite its usefulness in standardizing clinical research, the uptake of this scale has not been encouraging [68]. Our systematic review reports only 13 studies that have used this scale to report clinical progression. Gaps in reporting, with different studies grouping or failing to mention the number of patients for each score, undermines the use of a standardized scale to make sound accurate comparisons of clinical data. We recommend the use of the WHO clinical progression scale as a standard practice for studies on COVID-19 infection, with full reporting of all scores to enable comparison of study outcome measures and optimize the systematic analysis of clinical data.

There are several limitations to this systematic review, mostly stemming from considerable heterogeneity between articles. These include variations in participant inclusion criteria of studies, variations in outcome measures, variations in drugs used across the same class, variations in drug dosages, and variations in geographic locations and patient populations across studies. In addition, the retrospective nature of many studies, the limited sample sizes, and inadequate statistical adjustment for reported associations also adversely impact interpretability.

5. Conclusion

Data on pharmacological interventions to treat COVID-19 are rapidly evolving, and based on it, the recommendations have also been changed. In our systematic review, the recommendations were based on studies up till December 2021, and we have compared our recommendations with the WHO v7.1, which showed significant changes in recent treatment modalities of COVID-19 infection. Our understanding regarding the management of COVID-19 has evolved rapidly over the last two years and continues to do so. Given the urgent need to offer any therapeutic option, interim recommendations were often made based on the best available data at the time. These data were, however, often from studies that were exploratory or not as rigorously done. This is apparent in the disparate recommendation between the 2 guidelines and the systematic review (which is only looking at studies published during the early part of the pandemic). This also brings to light the need to continually assess the literature and be able to ready to change (previously established) therapeutic recommendations.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

Supplementary Figure 1. PRISMA flow diagram reporting various studies assessed for further evaluation and included in the review. Supplementary Figure 2. Risk of bias graph for quasiexperimental studies. Supplementary Figure 3. Risk of bias summary for quasiexperimental studies. Supplementary Figure 4. Risk of bias graph for randomized control trials. Supplementary Figure 5. Risk of bias summary for randomized control trials. Supplementary Figure 6. Risk of bias graph for case-control studies. Supplementary Figure 7. Risk of bias summary for case-control studies. Supplementary Figure 8. Risk of bias graph for observational cohort and cross-sectional Studies. Supplementary Figure 9. Risk of bias summary for observational cohort and cross-sectional studies. (Supplementary Materials)

References

WHO, WHO Coronavirus (COVID-19) Dashboard, WHO, Geneva, Switzerland, 2020.
Clinical Management Guidelines for COVID-19 Infections.https://covid.gov.pk/guideline 2020.
D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” International Journal of Surgery, vol. 8, no. 5, pp. 336–341, 2010.
View at: Publisher Site | Google Scholar
G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” BMJ, vol. 336, no. 7650, pp. 924–926, 2008.
View at: Publisher Site | Google Scholar
National Heart Lung and Blood Institute, National Institute of Health Study Quality Assessment Tool, National Heart, Lung, and Blood Institute, Karachi, Pakistan, 2017.
J. A. Sterne, J. Savović, M. J. Page et al., “RoB 2: a revised tool for assessing risk of bias in randomised trials,” British Molecular Journal, vol. 366, 2019.
View at: Publisher Site | Google Scholar
EPOC, CEPaOoC. Cochrane Effective Practice and Organisation of Care, EPOC, Islamabad, Pakistan, 2017.
S. Ramiro, R. L. M. Mostard, C. Magro-Checa et al., “Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study,” Annals of the Rheumatic Diseases, vol. 79, no. 9, pp. 1143–1151, 2020.
View at: Publisher Site | Google Scholar
M. Mikulska, L. A. Nicolini, A. Signori et al., “Tocilizumab and steroid treatment in patients with COVID-19 pneumonia,” PLoS One, vol. 15, no. 8, Article ID e0237831, 2020.
View at: Publisher Site | Google Scholar
M. Rubio-Rivas, M. Ronda, A. Padulles et al., “Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness,” International Journal of Infectious Diseases, vol. 101, pp. 290–297, 2020.
View at: Publisher Site | Google Scholar
A. Patel, K. Shah, M. Dharsandiya et al., “Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: a retrospective cohort study,” Indian Journal of Medical Microbiology, vol. 38, no. 1, pp. 116–122, 2020.
View at: Publisher Site | Google Scholar
P. Toniati, S. Piva, M. Cattalini et al., “Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy,” Autoimmunity Reviews, vol. 19, no. 7, Article ID 102568, 2020.
View at: Publisher Site | Google Scholar
C. A. Vu, K. J. DeRonde, A. D. Vega et al., “Effects of Tocilizumab in COVID-19 patients: a cohort study,” BMC Infectious Diseases, vol. 20, no. 1, pp. 964–1010, 2020.
View at: Publisher Site | Google Scholar
M. Zain Mushtaq, S. Bin Zafar Mahmood, B. Jamil, A. Aziz, and S. A. Ali, “Outcome of COVID-19 patients with use of tocilizumab: a single center experience,” International Immunopharmacology, vol. 88, Article ID 106926, 2020.
View at: Publisher Site | Google Scholar
S. Gupta, W. Wang, S. S. Hayek et al., “Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19,” JAMA Internal Medicine, vol. 181, no. 1, pp. 41–51, 2021.
View at: Publisher Site | Google Scholar
R. Capra, N. De Rossi, F. Mattioli et al., “Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia,” European Journal of Internal Medicine, vol. 76, pp. 31–35, 2020.
View at: Publisher Site | Google Scholar
R. Malekzadeh, A. Abedini, B. Mohsenpour et al., “Subcutaneous tocilizumab in adults with severe and critical COVID-19: a prospective open-label uncontrolled multicenter trial,” International Immunopharmacology, vol. 89, Article ID 107102, 2020.
View at: Publisher Site | Google Scholar
J. Martínez-Sanz, A. Muriel, R. Ron et al., “Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study,” Clinical Microbiology and Infections, vol. 27, no. 2, pp. 238–243, 2021.
View at: Google Scholar
F. Menzella, M. Fontana, C. Salvarani et al., “Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation,” Critical Care (London, England), vol. 24, no. 1, pp. 589–9, 2020.
View at: Publisher Site | Google Scholar
J. Rodríguez-Baño, J. Pachón, J. Carratalà et al., “Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19),” Clinical Microbiology Infection, vol. 27, 2020.
View at: Google Scholar
A. Sancho-López, F. Torres, V. Moreno-Torres et al., Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study, Springer, Berlin, Germany, 2020.
G. Guaraldi, M. Meschiari, A. Cozzi-Lepri et al., “Tocilizumab in patients with severe COVID-19: a retrospective cohort study,” The Lancet Rheumatology, vol. 2, no. 8, pp. e474–e484, 2020.
View at: Publisher Site | Google Scholar
T. Klopfenstein, S. Zayet, A. Lohse et al., “Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients,” International Journal of Infectious Diseases, vol. 99, pp. 491–495, 2020.
View at: Publisher Site | Google Scholar
G. Rojas-Marte, M. Khalid, O. Mukhtar et al., “Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study,” International Journal of Medicine, vol. 113, no. 8, pp. 546–550, 2020.
View at: Publisher Site | Google Scholar
R. Rossotti, G. Travi, N. Ughi et al., “Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis,” Journal of Infection, vol. 81, no. 4, pp. e11–e17, 2020.
View at: Publisher Site | Google Scholar
F. Perrone, M. C. Piccirillo, P. A. Ascierto et al., “Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial,” Journal of Translational Medicine, vol. 18, no. 1, pp. 405–411, 2020.
View at: Publisher Site | Google Scholar
M. A. Kaminski, S. Sunny, K. Balabayova et al., “Tocilizumab therapy for COVID-19: a comparison of subcutaneous and intravenous therapies,” International Journal of Infectious Diseases, vol. 101, pp. 59–64, 2020.
View at: Publisher Site | Google Scholar
A. R. Morrison, J. M. Johnson, K. M. Griebe et al., “Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab,” Journal of Autoimmunity, vol. 114, Article ID 102512, 2020.
View at: Publisher Site | Google Scholar
N. Nasir, F. Mahmood, K. Habib, I. Khanum, and B. Jamil, “Tocilizumab for COVID-19 acute respiratory distress syndrome: outcomes assessment using the WHO ordinal scale,” Cureus, vol. 12, no. 12, Article ID e12290, 2020.
View at: Publisher Site | Google Scholar
P. Gautret, J.-C. Lagier, P. Parola et al., “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,” International Journal of Antimicrobial Agents, vol. 56, no. 1, Article ID 105949, 2020.
View at: Publisher Site | Google Scholar
B. Stessel, C. Vanvuchelen, L. Bruckers et al., “Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study,” Thrombosis Research, vol. 194, pp. 209–215, 2020.
View at: Publisher Site | Google Scholar
K. Canoglu and B. Saylan, “Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection,” Annals of Saudi Medicine, vol. 40, no. 6, pp. 462–468, 2020.
View at: Publisher Site | Google Scholar
S. Jonmarker, J. Hollenberg, M. Dahlberg et al., “Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients,” Critical Care (London, England), vol. 24, no. 1, pp. 653–710, 2020.
View at: Publisher Site | Google Scholar
A. Hanif, S. Khan, N. Mantri et al., “Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York city hospital experience,” Annals of Hematology, vol. 99, no. 10, pp. 2323–2328, 2020.
View at: Publisher Site | Google Scholar
J. F. Llitjos, M. Leclerc, C. Chochois et al., “High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients,” Journal of Thrombosis and Haemostasis, vol. 18, no. 7, pp. 1743–1746, 2020.
View at: Publisher Site | Google Scholar
L. Ayerbe, C. Risco, and S. Ayis, “The association between treatment with heparin and survival in patients with COVID-19,” Journal of Thrombosis and Thrombolysis, vol. 50, no. 2, pp. 298–301, 2020.
View at: Publisher Site | Google Scholar
N. Tang, H. Bai, X. Chen, J. Gong, D. Li, and Z. Sun, “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy,” Journal of Thrombosis and Haemostasis, vol. 18, no. 5, pp. 1094–1099, 2020.
View at: Publisher Site | Google Scholar
H. H. Billett, M. Reyes-Gil, J. Szymanski et al., “Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality,” Thrombosis & Haemostasis, vol. 120, no. 12, pp. 1691–1699, 2020.
View at: Publisher Site | Google Scholar
G. N. Nadkarni, A. Lala, E. Bagiella et al., “Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study,” Journal of the American College of Cardiology, vol. 76, 2020.
View at: Google Scholar
Z. Pasquini, R. Montalti, C. Temperoni et al., “Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU,” Journal of Antimicrobial Chemotherapy, vol. 75, no. 11, pp. 3359–3365, 2020.
View at: Publisher Site | Google Scholar
S. A. Olender, K. K. Perez, A. S. Go et al., “Remdesivir for severe COVID-19 versus a cohort receiving standard of care,” Clinical Infectious Diseases, vol. 73, 2020.
View at: Google Scholar
S. Antinori, M. V. Cossu, A. L. Ridolfo et al., “Compassionate remdesivir treatment of severe COVID-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status,” Pharmacological Research, vol. 158, Article ID 104899, 2020.
View at: Publisher Site | Google Scholar
S. Tong, Y. Su, Y. Yu et al., “Ribavirin therapy for severe COVID-19: a retrospective cohort study,” International Journal of Antimicrobial Agents, vol. 56, no. 3, Article ID 106114, 2020.
View at: Publisher Site | Google Scholar
Y.-Q. Huang, S.-Q. Tang, X.-L. Xu et al., “No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, open-labeled prospective study,” Frontiers in Pharmacology, vol. 11, Article ID 1071, 2020.
View at: Publisher Site | Google Scholar
H. Abolghasemi, P. Eshghi, A. M. Cheraghali et al., “Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study,” Transfusion and Apheresis Science, vol. 59, no. 5, Article ID 102875, 2020.
View at: Publisher Site | Google Scholar
J. C. Olivares-Gazca, J. M. Priesca-Marín, M. Ojeda-Laguna et al., “Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study,” Revista de Investigación Clínica, vol. 72, no. 3, pp. 159–164, 2020.
View at: Publisher Site | Google Scholar
S. T. H. Liu, H.-M. Lin, I. Baine et al., “Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study,” Nature Medicine, vol. 26, no. 11, pp. 1708–1713, 2020.
View at: Publisher Site | Google Scholar
A. S. Bourinbaiar and E. C. Fruhstorfer, “The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents,” Life Sciences, vol. 59, no. 23, 1996.
View at: Publisher Site | Google Scholar
D. E. Freedberg, J. Conigliaro, T. C. Wang et al., “Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study,” Gastroenterology, vol. 159, no. 3, pp. 1129–1131, 2020.
View at: Publisher Site | Google Scholar
J. F. Mather, R. L. Seip, and R. G. McKay, “Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19,” American Journal of Gastroenterology, vol. 115, no. 10, pp. 1617–1623, 2020.
View at: Publisher Site | Google Scholar
Z. Shao, Y. Feng, L. Zhong et al., “Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study,” Clinical & translational immunology, vol. 9, no. 10, Article ID e1192, 2020.
View at: Publisher Site | Google Scholar
N. Gharebaghi, R. Nejadrahim, S. J. Mousavi, S. R. Sadat-Ebrahimi, and R. Hajizadeh, “The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial,” BMC Infectious Diseases, vol. 20, no. 1, pp. 786–788, 2020.
View at: Publisher Site | Google Scholar
N. Schlesinger, B. L. Firestein, and L. Brunetti, “Colchicine in COVID-19: an old drug, new use,” Current Pharmacology Reports, vol. 6, no. 4, pp. 137–145, 2020.
View at: Publisher Site | Google Scholar
M. Scarsi, S. Piantoni, E. Colombo et al., “Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome,” Annals of the Rheumatic Diseases, vol. 79, no. 10, pp. 1286–1289, 2020.
View at: Publisher Site | Google Scholar
Health NIO, Therapeutic Management of Hospitalized Adults with COVID-19, Health NIO, Karachi, Sindh, Pakistan, 2021.
R. A. Siemieniuk, J. J. Bartoszko, L. Ge et al., “Drug treatments for COVID-19: living systematic review and network meta-analysis,” Bmj (Clinical research ed.), vol. 370, Article ID m2980, 2020.
View at: Publisher Site | Google Scholar
S. Juul, E. E. Nielsen, J. Feinberg et al., “Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project),” PLoS Medicine, vol. 17, no. 9, Article ID e1003293, 2020.
View at: Publisher Site | Google Scholar
J. Wu, J. Huang, G. Zhu et al., “Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China,” Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 12, pp. e4230–e4239, 2020.
View at: Publisher Site | Google Scholar
X. You, C.-H. Wu, Y.-N. Fu et al., “The use of methylprednisolone in COVID-19 patients: a propensity score matched retrospective cohort study,” PLoS One, vol. 15, no. 12, Article ID e0244128, 2020.
View at: Publisher Site | Google Scholar
A. Sarfraz, Z. Sarfraz, M. Sarfraz, H. Aftab, and Z. Pervaiz, “Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies,” Turkish Journal of Medical Sciences, vol. 51, no. 3, pp. 890–897, 2021.
View at: Publisher Site | Google Scholar
M. Fernández‐Ruiz, F. López‐Medrano, M. A. Pérez‐Jacoiste Asín et al., “Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study,” Journal of Medical Virology, vol. 93, no. 2, pp. 831–842, 2021.
View at: Google Scholar
D. Yan, X. Y. Liu, Y. N. Zhu et al., “Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection,” European Respiratory Journal, vol. 56, no. 1, 2020.
View at: Publisher Site | Google Scholar
A. Agarwal, A. Mukherjee, G. Kumar, P. Chatterjee, T. Bhatnagar, and P. Malhotra, “Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial),” Bmj, vol. 371, 2020.
View at: Publisher Site | Google Scholar
L. Li, W. Zhang, Y. Hu et al., “Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19,” Jama, vol. 324, no. 5, pp. 460–470, 2020.
View at: Publisher Site | Google Scholar
M. E. Balcells, L. Rojas, N. Le Corre et al., “Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase ii clinical trial,” 2020, https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1.
View at: Google Scholar
V. A. Simonovich, L. D. Burgos Pratx, P. Scibona et al., “A randomized trial of convalescent plasma in COVID-19 severe pneumonia,” New England Journal of Medicine, vol. 384, no. 7, pp. 619–629, 2021.
View at: Publisher Site | Google Scholar
WHO, WHO COVID-19 Solidarity Therapeutics Trial, WHO, Geneva, Switzerland, 2021.
J. C. Marshall, S. Murthy, J. Diaz et al., “A minimal common outcome measure set for COVID-19 clinical research,” The Lancet Infectious Diseases, vol. 20, no. 8, pp. e192–e197, 2020.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Sarah Nadeem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

817

Downloads

788

Citations